Esmolol nonclinical toxicology: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 11: | Line 11: | ||
{{FDA}} | {{FDA}} | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drugs]] | [[Category:Drugs]] |
Revision as of 00:04, 21 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Nonclinical Toxicology
Because of its short term usage nocarcinogenicity, mutagenicity, or reproductive performance studies have been conducted with esmolol.[1]
References
Adapted from the FDA Package Insert.